Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

m-RESIST

Financiado

Cerrado

Mobile Therapeutic Attention for Patients with Treatment Resistant Schizophrenia

In European Union approximately 5 million people suffer from psychotic disorders. Between 30-50% can be considered resistant to treatment, and 10-20% ultra-resistant. These patients present persistent positive symptomatology, requ... ver más

31/12/2017

FUNDACIO TICSALUT

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

FUNDACIO TICSALUT No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-12-31

PHC-26-2014: Self management of health and disea... Scope:Specific challenge: Empowering citizens to manage their own health and disease will result in...

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

FUNDACIO TICSALUT

366.25K€ | Lider

HEALTH NETWORK SERVICES SL E...

RESEARCH UNIVERSITY INSTITUT...

279.13K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EUIN2013-50935 M-RESIST: PROGRAMA DE ATENCION TERAPEUTICA M-HEALTH EN PACIE... 25K€ Cerrado

ICare Integrating Technology into Mental Health Care Delivery in E... 6M€ Cerrado

iManageCancer iManageCancer Empowering patients and strengthening self m... 5M€ Cerrado

EUIN2015-A-62589 CAPACITACION Y FORTALECIMIENTO DEL PACIENTE CON TRASTORNO ME... Cerrado

PID2019-108408RB-C21 ACTIVE UP: DIMENSION TECNOLOGICA Y CIENTIFICA 65K€ Cerrado

SOLUCIÓN MHEALTH INTELIGENTE E INNOVADORA PAR... SOLUCIÓN MHEALTH INTELIGENTE E INNOVADORA PARA EL TRATAMIENT... 811K€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2014-12-12
Fecha Fin: 2017-12-31

Líder del proyecto

FUNDACIO TICSALUT No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In European Union approximately 5 million people suffer from psychotic disorders. Between 30-50% can be considered resistant to treatment, and 10-20% ultra-resistant. These patients present persistent positive symptomatology, require extensive periods of hospital care, and have a greater risk of excess mortality and multi-morbidity. In addition, a high proportion of the total cost for treating schizophrenia is spent on this population (Kennedy et al., 2013). Intervention strategies based on mHealth have demonstrated their ability to support and promote self-management-based strategies. Evidence from studies point to the importance of engaging patients actively in their own treatment. This active role helps to improve adherence to treatment, and to reduce persistent symptoms severity, relapses and hospitalizations (Mueser et al., 2002). m-RESIST aims to develop an intervention programme based on mHealth to allow patients suffering from resistant schizophrenia to self-manage their condition (resistant schizophrenia and its associated comorbidities, e.g. somatic disorders and addictions). This may facilitate acceptance and involvement of patients with their own treatment, as well as of caregivers. Moreover this programme could provide a new tool to the psychiatrist, psychologists working together with other health care professionals, to better monitor patients, through a personalised and optimised therapeutic process. m-resist will (1) develop and validate an mHealth solution aimed to reduce the severity of episodes and further complications; (2) involve and promote participation of patients and caregivers in the therapeutic process increasing the awareness of patient and caregiver about the nature of the illness and its consequences, benefits of treatment and needs for healthy habits and promoting an active and collaborative role with the medical team in the treatment decision-making procedure.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores